Clinical Trial

Trial Protocol ID USOR 22320_D7630C00001_TROPION-Breast05

Trial Description

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator’s Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Carol Tweed, MD

Disease Types

Sponsor

  • AstraZeneca

ClinicalTrials.gov NCT ID

  • NCT06103864